GEMTESA
Drug
UROVANT SCIENCES INC
Total Payments
$16.9M
Transactions
177,056
Doctors
35,179
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.0M | 53,583 | 18,681 |
| 2023 | $4.8M | 58,149 | 18,257 |
| 2022 | $7.1M | 47,210 | 14,044 |
| 2021 | $2.0M | 18,114 | 8,530 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.8M | 1,955 | 63.8% |
| Food and Beverage | $3.3M | 170,889 | 19.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 1,373 | 10.6% |
| Consulting Fee | $625,503 | 322 | 3.7% |
| Travel and Lodging | $429,604 | 1,579 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.0% |
| Education | $4,469 | 931 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$10.8M
1,955 transactions
General
$6.1M
175,101 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | UROVANT SCIENCES INC | $4.6M | 0 |
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | Sumitomo Pharma America, Inc. | $1.7M | 0 |
| A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF VIBEGRON IN MEN WITH OVERACTIVE BLADDER (OAB) SYMPTOMS ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH) | Sumitomo Pharma America, Inc. | $1.1M | 0 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | UROVANT SCIENCES INC | $700,844 | 0 |
| A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | Sumitomo Pharma America, Inc. | $692,029 | 0 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | UROVANT SCIENCES INC | $490,024 | 0 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | UROVANT SCIENCES INC | $426,237 | 0 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | Sumitomo Pharma America, Inc. | $352,751 | 0 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | UROVANT SCIENCES INC | $230,828 | 0 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | Sumitomo Pharma America, Inc. | $209,837 | 0 |
| A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF VIBEGRON IN MEN WITH OVERACTIVE BLADDER (OAB) SYMPTOMS ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH) | Sumitomo Pharma America, Inc. | $106,052 | 0 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | Sumitomo Pharma America, Inc. | $92,038 | 0 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | UROVANT SCIENCES INC | $7,500 | 0 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | UROVANT SCIENCES INC | $5,000 | 0 |
| Composur | UROVANT SCIENCES INC | $1,976 | 0 |
Top Doctors Receiving Payments for GEMTESA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Watertown, MA | $10.8M | 1,967 |
| , M.D | Family Medicine | Jackson, MI | $240,360 | 297 |
| , MD | Urology | Brighton, MA | $213,387 | 278 |
| , CRNP | Adult Health | Philadelphia, PA | $188,599 | 363 |
| , MD | Urology | Greensboro, NC | $139,902 | 135 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Charlotte, NC | $138,333 | 209 |
| , D.O | Urology | Huntersville, NC | $130,116 | 109 |
| , D.O | Specialist | Philadelphia, PA | $91,514 | 137 |
| , M.D | Urology | Webster, TX | $91,128 | 167 |
| , M.D | Urology | Owings Mills, MD | $80,422 | 147 |
| , MD | Specialist | Seattle, WA | $78,689 | 85 |
| , MD | Urology | San Antonio, TX | $76,658 | 93 |
| , MD | Family Medicine | Kingwood, TX | $72,948 | 172 |
| , MD | Internal Medicine | Miami, FL | $66,460 | 135 |
| , MD | Urology | New York, NY | $65,281 | 55 |
| , M.D | Neurology | East Orange, NJ | $64,002 | 63 |
| , MD | Geriatric Medicine | Dayton, OH | $63,685 | 81 |
| , MD | Urology | Santa Barbara, CA | $62,898 | 84 |
| Shenelle Wilson | Urology | Mcdonough, GA | $49,434 | 54 |
| , MD | Urology | Charleston, SC | $44,202 | 21 |
| , M.D | Urology | Baltimore, MD | $44,160 | 66 |
| , M.D | General Practice | Fort Wayne, IN | $36,678 | 79 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Skokie, IL | $34,798 | 42 |
| , MD | Obstetrics & Gynecology | Philadelphia, PA | $34,362 | 31 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Houston, TX | $32,403 | 44 |
Ad
Manufacturing Companies
- UROVANT SCIENCES INC $8.7M
- Sumitomo Pharma America, Inc. $7.8M
- Sunovion Pharmaceuticals Inc. $424,652
Product Information
- Type Drug
- Total Payments $16.9M
- Total Doctors 35,179
- Transactions 177,056
About GEMTESA
GEMTESA is a drug associated with $16.9M in payments to 35,179 healthcare providers, recorded across 177,056 transactions in the CMS Open Payments database. The primary manufacturer is UROVANT SCIENCES INC.
Payment data is available from 2021 to 2024. In 2024, $3.0M was paid across 53,583 transactions to 18,681 doctors.
The most common payment nature for GEMTESA is "Unspecified" ($10.8M, 63.8% of total).
GEMTESA is associated with 15 research studies, including "A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)" ($4.6M).